Susan Chor's questions to Amylyx Pharmaceuticals Inc (AMLX) leadership • Q2 2025
Question
Susan Chor, on for Tim Anderson, asked about the risk of the event-driven LUCIDITY trial being delayed due to a lack of events and the assumptions underpinning the H1 2026 data readout timeline.
Answer
Chief Medical Officer Dr. Camille Bedrosian stated they do not anticipate event rates impacting the timeline, referencing the substantial event reductions seen in prior studies. Co-CEO & Co-Founder Josh Cohen reiterated the timeline, confirming enrollment completion is expected by year-end 2025, with data in H1 2026, as the timeline is driven by enrollment, not event rate.